Browse conferences
Fields
All fields →
Health & Medicine
Computing & Data
Engineering & Technology
Arts & Humanities
Social & Behavioural Sciences
Physical Sciences
Earth & Environment
Education
Business & Economics
Life Sciences
Agriculture & Veterinary
Politics & Public Policy
Law & Criminology
Mathematics & Statistics
Open callsBlogFor organizersAdd your event — freeLog inSign up
This edition has ended.23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC 2025) was held 4–6 Dec 2025 in Los Angeles. The information below is kept for reference.
Follow the series

23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC 2025)

Part of the World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) series →

Dates4–6 Dec 2025
LocationLos Angeles, United States
SubmissionsNot listed
RegistrationClosed
FormatHybrid
FieldHealth & Medicine · Cardiology
OrganizerNot listed

About & call for papers

The 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC 2025) is dedicated to insulin resistance, obesity, diabetes, related Kidney, cardiovascular disease and fatty liver morbidity. Topics - The effect of lipotoxicity and th… Read more

The 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC 2025) is dedicated to insulin resistance, obesity, diabetes, related Kidney, cardiovascular disease and fatty liver morbidity. Topics - The effect of lipotoxicity and the pathophysiology of CVD - The relationship between diabetes, obesity, and congestive heart failure - The roles of diabetes in the development of micro & macrovascular conditions: kidney disease, retinopathy, neuropathy, CVD and strokes - The role of obesity in the development of cardiometabolic conditions - The role of incretins in the management of diabetes, obesity, and related complications - Comprehensive management of diabetes, through addressing obesity, hypertension, dyslipidemia and hyperglycemia - The role of SGLT2i & GLP1ra for primary prevention of cardiovascular morbidity & mortality in patients with T2D - The evidence supporting the use of SGLT2 inhibitors and GLP1ra`s to reduce cardiovascular morbidity & mortality in patients with T2D and established CVD - Fatty liver disease and its relationship to diabetes and CVD - The role of PCSK9 inhibitors in preventing CV morbidity in people with established ASCVD - The impact on clinical practice of recent CVD, CHF & CKD outcome trials - The pathogenesis of liver and muscle insulin resistance, the role of adipose tissue and of the mitochondria in hyperglycemia and ASCVD - Best practices for the prevention and management of CHF - The impact on clinical practice of lipid CV outcome trials, including IMPROVE -IT, FOURIER, REDUCE -IT, ODYSSEY-Outcomes - The role of Coagulation and new anti-coagulation agents in prevention of CVD and CVA - The Cardiorenal Syndrome - Reducing morbidity and mortality through being able to match the correct medications to the appropriate patients Who should Attend - Endocrinologists - Cardiologists - Oncologists - Gastroenterologists - Diabetologists - Internists - Pediatricians - OBGYNs - Nurse practitioners - Dietitians - Pharmacists - Other health care professionals

Venue

Hilton Hotel Universal City, Los Angeles, CA

Los Angeles, United States

Open Hilton Hotel Universal City, Los Angeles, CA in maps ↗

No street address is on file for this listing — what the organizer gave is above. Suggest the venue address →

Similar conferences

Frequently asked

When is the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC 2025) submission date?
This edition has ended. The series page shows whether a newer edition is accepting submissions.
Where was 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC 2025) held?
It was held at the Hilton Hotel Universal City, Los Angeles, CA, Los Angeles, United States, with remote attendance offered as well.
Can I attend 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC 2025) remotely?
Yes — 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC 2025) is hybrid, so remote attendance is offered alongside the venue.